UTMD Stock Overview
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry.
Utah Medical Products Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$86.97|
|52 Week High||US$133.87|
|52 Week Low||US$80.31|
|1 Month Change||4.48%|
|3 Month Change||-3.91%|
|1 Year Change||-0.034%|
|3 Year Change||-9.12%|
|5 Year Change||20.12%|
|Change since IPO||1,204.55%|
Recent News & Updates
Utah Medical Products (NASDAQ:UTMD) Is Due To Pay A Dividend Of US$0.29
Utah Medical Products, Inc. ( NASDAQ:UTMD ) has announced that it will pay a dividend of US$0.29 per share on the 6th...
|UTMD||US Medical Equipment||US Market|
Return vs Industry: UTMD exceeded the US Medical Equipment industry which returned -23.7% over the past year.
Return vs Market: UTMD exceeded the US Market which returned -18.5% over the past year.
|UTMD Average Weekly Movement||2.6%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: UTMD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: UTMD's weekly volatility (3%) has been stable over the past year.
About the Company
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies.
Utah Medical Products Fundamentals Summary
|UTMD fundamental statistics|
Is UTMD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UTMD income statement (TTM)|
|Cost of Revenue||US$18.91m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||4.20|
|Net Profit Margin||30.35%|
How did UTMD perform over the long term?See historical performance and comparison
1.3%Current Dividend Yield
Is UTMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UTMD?
Other financial metrics that can be useful for relative valuation.
|What is UTMD's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does UTMD's PE Ratio compare to its peers?
|UTMD PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: UTMD is good value based on its Price-To-Earnings Ratio (20.7x) compared to the peer average (36.6x).
Price to Earnings Ratio vs Industry
How does UTMD's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Earnings vs Industry: UTMD is good value based on its Price-To-Earnings Ratio (20.7x) compared to the US Medical Equipment industry average (34.8x)
Price to Earnings Ratio vs Fair Ratio
What is UTMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||20.7x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate UTMD's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of UTMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: UTMD ($86.97) is trading below our estimate of fair value ($149.66)
Significantly Below Fair Value: UTMD is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UTMD's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Utah Medical Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Utah Medical Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Utah Medical Products is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
How has Utah Medical Products performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UTMD has high quality earnings.
Growing Profit Margin: UTMD's current net profit margins (30.3%) are higher than last year (25.3%).
Past Earnings Growth Analysis
Earnings Trend: UTMD's earnings have grown by 2.5% per year over the past 5 years.
Accelerating Growth: UTMD's earnings growth over the past year (43.2%) exceeds its 5-year average (2.5% per year).
Earnings vs Industry: UTMD earnings growth over the past year (43.2%) exceeded the Medical Equipment industry 12.9%.
Return on Equity
High ROE: UTMD's Return on Equity (14%) is considered low.
Discover strong past performing companies
How is Utah Medical Products's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: UTMD's short term assets ($79.5M) exceed its short term liabilities ($6.1M).
Long Term Liabilities: UTMD's short term assets ($79.5M) exceed its long term liabilities ($4.5M).
Debt to Equity History and Analysis
Debt Level: UTMD is debt free.
Reducing Debt: UTMD has not had any debt for past 5 years.
Debt Coverage: UTMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: UTMD has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Utah Medical Products's current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: UTMD's dividend (1.33%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.57%).
High Dividend: UTMD's dividend (1.33%) is low compared to the top 25% of dividend payers in the US market (4.24%).
Stability and Growth of Payments
Stable Dividend: UTMD's dividends per share have been stable in the past 10 years.
Growing Dividend: UTMD's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (20.5%), UTMD's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (21.2%), UTMD's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Kevin Cornwell (74 yo)
Mr. Kevin L. Cornwell has been the Chairman of the Board at Utah Medical Products Inc. since 1996 and its President and Chief Executive Officer since December 1992. Mr. Cornwell has been Secretary of Utah...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD494.21K) is below average for companies of similar size in the US market ($USD2.84M).
Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.
Experienced Board: UTMD's board of directors are seasoned and experienced ( 25.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: UTMD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Utah Medical Products, Inc.'s employee growth, exchange listings and data sources
- Name: Utah Medical Products, Inc.
- Ticker: UTMD
- Exchange: NasdaqGS
- Founded: 1978
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$317.005m
- Shares outstanding: 3.64m
- Website: https://www.utahmed.com
Number of Employees
- Utah Medical Products, Inc.
- 7043 South 300 West
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.